Woodline Partners LP Allogene Therapeutics, Inc. Transaction History

Woodline Partners LP

$17.6 Billion
Q2 2025

A detailed history of Woodline Partners LP transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 4,360,608 shares of ALLO stock, worth $4.49 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

4,360,608

Previous 4,360,608 -0.0%

Holding current value

$4.49 Million

Previous $6.37 Million 22.6%

% of portfolio

0.03%

Previous 0.04%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$1.4 - $2.84 $526 - $1,067	376 Added 0.01%	4,360,608 $6.37 Million
Q4 2024 Feb 14, 2025	SELL	$1.84 - $3.22 $7,485 - $13,098	-4,068 Reduced 0.09%	4,360,232 $9.29 Million
Q3 2024 Nov 14, 2024	BUY	$2.08 - $3.5 $11,046 - $18,588	5,311 Added 0.12%	4,364,300 $12.2 Million
Q2 2024 Aug 14, 2024	BUY	$2.23 - $4.38 $3.85 Million - $7.56 Million	1,725,013 Added 65.49%	4,358,989 $10.2 Million
Q1 2024 May 15, 2024	BUY	$2.92 - $5.63 $164,909 - $317,959	56,476 Added 2.19%	2,633,976 $11.8 Million
Q4 2023 Feb 14, 2024	SELL	$2.28 - $3.5 $6.24 Million - $9.58 Million	-2,736,415 Reduced 51.5%	2,577,500 $8.27 Million
Q3 2023 Nov 14, 2023	BUY	$3.17 - $5.96 $1,315 - $2,473	415 Added 0.01%	5,313,915 $16.8 Million
Q2 2023 Aug 14, 2023	BUY	$4.53 - $6.74 $14.1 Million - $21 Million	3,121,070 Added 142.36%	5,313,500 $26.4 Million
Q1 2023 May 15, 2023	SELL	$4.92 - $8.21 $3.59 Million - $5.99 Million	-729,032 Reduced 24.95%	2,192,430 $10.8 Million
Q4 2022 Feb 14, 2023	SELL	$5.62 - $11.11 $9.02 Million - $17.8 Million	-1,604,960 Reduced 35.46%	2,921,462 $18.4 Million
Q3 2022 Nov 14, 2022	SELL	$10.32 - $17.28 $13.8 Million - $23 Million	-1,333,257 Reduced 22.75%	4,526,422 $48.9 Million
Q2 2022 Aug 15, 2022	BUY	$6.78 - $12.28 $36.8 Million - $66.7 Million	5,427,529 Added 1255.94%	5,859,679 $66.8 Million
Q1 2022 May 16, 2022	SELL	$7.65 - $15.29 $519,779 - $1.04 Million	-67,945 Reduced 13.59%	432,150 $3.94 Million
Q4 2021 Feb 14, 2022	SELL	$13.13 - $24.52 $4.1 Million - $7.67 Million	-312,635 Reduced 38.47%	500,095 $7.46 Million
Q3 2021 Nov 15, 2021	BUY	$21.01 - $27.64 $2.69 Million - $3.54 Million	127,975 Added 18.69%	812,730 $20.9 Million
Q2 2021 Aug 16, 2021	BUY	$23.49 - $35.8 $284,487 - $433,573	12,111 Added 1.8%	684,755 $17.9 Million
Q1 2021 May 17, 2021	BUY	$25.79 - $39.02 $2.71 Million - $4.1 Million	105,105 Added 18.52%	672,644 $23.7 Million
Q4 2020 Feb 16, 2021	BUY	$25.24 - $43.45 $4.22 Million - $7.27 Million	167,306 Added 41.8%	567,539 $14.3 Million
Q3 2020 Nov 16, 2020	BUY	$32.38 - $44.96 $8.79 Million - $12.2 Million	271,605 Added 211.16%	400,233 $15.1 Million
Q2 2020 Aug 14, 2020	BUY	$18.39 - $54.04 $2.37 Million - $6.95 Million	128,628 New	128,628 $5.51 Million

Others Institutions Holding ALLO

# of Institutions

169

Shares Held

162M

Call Options Held

146K

Put Options Held

97.1K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $148M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.

Account

Woodline Partners LP Allogene Therapeutics, Inc. Transaction History